BRIDGEWATER, NJ -- (MARKET WIRE) -- September 19, 2006 -- Sapphire Therapeutics, Inc., a private biopharmaceutical company that inlicenses compounds acting within the ghrelin pathway and develops them as treatments for metabolic and oncologic diseases, has licensed a highly potent and selective small-molecule ghrelin mimetic, ipamorelin, from Novo Nordisk.
